Back to User profile » Dr Yi-Long Wu
Papers published by Dr Yi-Long Wu:
Effect of Dose Adjustments on the Safety and Efficacy of Afatinib in Chinese Patients with EGFR-Mutated Non-Small Cell Lung Cancer Who Participated in the LUX-Lung Clinical Trial Program
Tu HY, Wu YL
OncoTargets and Therapy 2020, 13:12539-12547
Published Date: 7 December 2020
Familial association of lung cancer with liver cancer in first-degree relatives
Xu CR, Lin H, Su J, Zhang XC, Huang YS, Yang XN, Zhou Q, Yang JJ, Zhong WZ, Wu YL
Cancer Management and Research 2019, 11:5813-5819
Published Date: 28 June 2019
Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial
Wu YL, Xu CR, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Märten A, Fan J, Peil B, Zhou C
OncoTargets and Therapy 2018, 11:8575-8587
Published Date: 30 November 2018
Personalized treatment strategies for non-small-cell lung cancer in Chinese patients: the role of crizotinib
Niu FY, Wu YL
OncoTargets and Therapy 2015, 8:999-1007
Published Date: 2 May 2015
Prevalence of driver mutations in non-small-cell lung cancers in the People’s Republic of China
Gou LY, Wu YL
Lung Cancer: Targets and Therapy 2014, 5:1-9
Published Date: 12 February 2014